2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 24.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23.4.Moleculin broadens the narrative: Annamycin opens the door to pancreatic cancer Moleculin Biotech (MBRX) today, April 23, 2026, presented new research results at the major cancer conference AACR. The results come from so-called preclinical studies, i.e., tests in a laboratory environment and on animals that are performed before a drug is tested on humans. The company's lead candidate Annamycin – in a form where the drug is packaged in small fat vesicles (liposomes) to reach better in the body – extended survival by more than 60% in models of metastatic pancreatic cancer (PDAC). The drug also accumulated to a significantly higher degree in the tumor itself compared to the classic cancer drug doxorubicin, which means that more of the effect ends up where it is needed. What is truly exciting is that Annamycin attracted the body's own immune cells (T-cells) into the tumor. Pancreatic cancer is often called a "cold" tumor – the immune system does not recognize it and does not attack. This is precisely why modern immunotherapies, so-called checkpoint inhibitors (for example, Keytruda), have so far worked poorly in this disease. If Annamycin can "warm up" the tumor and let in the immune system, a completely new treatment pathway opens up, especially in combination with today's modern cancer drugs such as checkpoint inhibitors and KRAS inhibitors (a new type that attacks a common cancer mutation). The competitive advantages are further strengthened. Annamycin does not damage the heart, which is the major limitation of today's anthracyclines and allows for higher and more doses. The drug also bypasses the resistance mechanisms that often cause cancer cells to stop responding to treatment upon relapse. Together with the new immunological effect, this makes Annamycin an interesting "backbone treatment" that can be combined with other modern drugs. The market potential is thus broadened from blood cancer to solid tumors, and pancreatic cancer is a multi-billion indication where the need for better treatments is enormous. Regulatorily, there are good opportunities to obtain special fast tracks at the FDA – such as Orphan Drug (for rare diseases), Fast Track, and possibly Breakthrough Therapy – all of which can shorten the time to approval and market. Looking ahead, three important events that could move the stock are expected: a poster presentation at the major cancer conference ASCO at the end of May on Annamycin's cardiac safety, the long-awaited interim readout of the MIRACLE study (the ongoing Phase 3 study in relapsed blood cancer, AML) on 45 patients around mid-2026, and possibly the kick-off for combination studies in solid tumors. The risks should not be underestimated – the company needs more funding going forward, and promising laboratory results do not always translate to success in humans. But if MIRACLE delivers, MBRX goes from an interesting small research stock to a validated Phase 3 case, and today's news shows that the pipeline holds more opportunities than what today's market capitalization reflects.
·23.4.@Drill do you have any thoughts on the good announcement from Moleculin? I'm thinking more specifically about the prestudy presentation they had today?·23.4.Yes, I think it's really good news. What makes the preclinical PDAC data extra interesting is not just the 60% survival extension but that Annamycin actually draws T-cells into the tumor. Pancreatic cancer is a classic “cold” tumor where checkpoint inhibitors have barely worked – if Annamycin can warm up the tumors, the door opens to combinations with Keytruda and KRAS inhibitors, which is precisely the type of backbone Big Pharma is looking for. I still want to remind you that it's preclinical – the path to the clinic is long, and that's where many oncology candidates fail. But as a complement to the ongoing MIRACLE study in AML, it significantly broadens the story and shows that Annamycin's mechanism holds up even outside hematology. For me, it's a clear de-risking moment ahead of this summer's major unblinding.- ·5.3.Any idea about upcoming price with good data and/or really good data?? And when? Q1 or Q2 2026?
·18.3.Hoping for 3-5 USD and some preliminary data should come before Q2. I am still getting into the case so I have only put money into 500 units to start with today. - ·14.1.MBRX – Moleculin: 0% cardiotoxicity confirmed + Phase 3 data underway – valuation isn't keeping up! Two press releases from Moleculin Biotech (MBRX) on January 12 & 13 have given us shareholders much to ponder – and even more to hope for. - January 12: The company presents its roadmap for 2026–2028. Focus on Annamycin (AML, STS, pancreatic cancer) and WP1066 (STAT3 inhibitor for brain tumors). The Phase 3 study MIRACLE is now global (9 countries, 46+ sites), and the first unblinding (45 patients) will occur Q1 2026. External studies underway via Atlantic Health, Emory, and Northwestern. - January 13: An independent expert confirms that Annamycin does not cause any cardiotoxicity – not even in patients who received doses far exceeding the FDA's lifetime limit for anthracyclines. 90 patients have now been evaluated, 65 of whom received >550 mg/m², one received >6500(!) mg/m² – without heart damage. What does this mean? - Annamycin could become the first truly non-cardiotoxic anthracycline – a class where heart damage is the biggest limitation. - The safety profile is now validated by an external expert – an important regulatory milestone. - The market potential is enormous: anthracyclines are used in ~50% of all cancer treatments, but are currently limited by cardiac side effects. - The MIRACLE study is well underway – efficacy data from the first 45 patients is expected Q1 2026. - External collaborations (Atlantic Health, Emory, Northwestern) provide validation and reduce capital requirements. Valuation – a ticking bomb? Moleculin is currently valued at approximately 12.5 MUSD. It is a Phase 3 company with a potential blockbuster in oncology – a market where similar companies are often valued at 10–20x more in the equivalent phase. Add to this: • A confirmed safety profile that eliminates one of the biggest regulatory risks. • A pipeline with several candidates (Annamycin, WP1066, WP1122). • A Phase 3 study that will soon be unblinded. • A potential first-in-class product in an area with a billion-dollar market. …and it's hard to understand why the market hasn't already started pricing this in. It smells like strong undervaluation. Risks remain: • Efficacy data is still crucial. Safety is necessary but not sufficient. • Moleculin is a microcap company without revenue – continued development requires capital or a partner. • The market has not yet reacted strongly – the stock even fell slightly on the news. Conclusion: Moleculin has now proven that Annamycin is safe for the heart – something no other anthracycline has achieved. If efficacy data from the MIRACLE study is also positive, this could be a paradigm shift in oncology. WP1066 is also a dark horse with the potential to break through in brain tumors and immunotherapy. It is high risk – but also high potential. 2026 could be the year Moleculin goes from being a speculative microcap to becoming an acquisition candidate or licensing partner for Big Pharma. This could be Moleculin's “make or break” year! MBRX – “Next-gen anthracycline”·23.2.I am on the same page and it is clear that the data could be even better, considering that the preliminary MIRACLE results indicate a CR/CRh frequency of 40%, significantly higher than the ~17–18% seen with standard treatment in relapsed AML. This suggests that Annamycin + cytarabine can provide significantly better efficacy than existing alternatives, which bodes well for the study's continuation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23.4.Moleculin broadens the narrative: Annamycin opens the door to pancreatic cancer Moleculin Biotech (MBRX) today, April 23, 2026, presented new research results at the major cancer conference AACR. The results come from so-called preclinical studies, i.e., tests in a laboratory environment and on animals that are performed before a drug is tested on humans. The company's lead candidate Annamycin – in a form where the drug is packaged in small fat vesicles (liposomes) to reach better in the body – extended survival by more than 60% in models of metastatic pancreatic cancer (PDAC). The drug also accumulated to a significantly higher degree in the tumor itself compared to the classic cancer drug doxorubicin, which means that more of the effect ends up where it is needed. What is truly exciting is that Annamycin attracted the body's own immune cells (T-cells) into the tumor. Pancreatic cancer is often called a "cold" tumor – the immune system does not recognize it and does not attack. This is precisely why modern immunotherapies, so-called checkpoint inhibitors (for example, Keytruda), have so far worked poorly in this disease. If Annamycin can "warm up" the tumor and let in the immune system, a completely new treatment pathway opens up, especially in combination with today's modern cancer drugs such as checkpoint inhibitors and KRAS inhibitors (a new type that attacks a common cancer mutation). The competitive advantages are further strengthened. Annamycin does not damage the heart, which is the major limitation of today's anthracyclines and allows for higher and more doses. The drug also bypasses the resistance mechanisms that often cause cancer cells to stop responding to treatment upon relapse. Together with the new immunological effect, this makes Annamycin an interesting "backbone treatment" that can be combined with other modern drugs. The market potential is thus broadened from blood cancer to solid tumors, and pancreatic cancer is a multi-billion indication where the need for better treatments is enormous. Regulatorily, there are good opportunities to obtain special fast tracks at the FDA – such as Orphan Drug (for rare diseases), Fast Track, and possibly Breakthrough Therapy – all of which can shorten the time to approval and market. Looking ahead, three important events that could move the stock are expected: a poster presentation at the major cancer conference ASCO at the end of May on Annamycin's cardiac safety, the long-awaited interim readout of the MIRACLE study (the ongoing Phase 3 study in relapsed blood cancer, AML) on 45 patients around mid-2026, and possibly the kick-off for combination studies in solid tumors. The risks should not be underestimated – the company needs more funding going forward, and promising laboratory results do not always translate to success in humans. But if MIRACLE delivers, MBRX goes from an interesting small research stock to a validated Phase 3 case, and today's news shows that the pipeline holds more opportunities than what today's market capitalization reflects.
- ·23.4.@Drill do you have any thoughts on the good announcement from Moleculin? I'm thinking more specifically about the prestudy presentation they had today?·23.4.Yes, I think it's really good news. What makes the preclinical PDAC data extra interesting is not just the 60% survival extension but that Annamycin actually draws T-cells into the tumor. Pancreatic cancer is a classic “cold” tumor where checkpoint inhibitors have barely worked – if Annamycin can warm up the tumors, the door opens to combinations with Keytruda and KRAS inhibitors, which is precisely the type of backbone Big Pharma is looking for. I still want to remind you that it's preclinical – the path to the clinic is long, and that's where many oncology candidates fail. But as a complement to the ongoing MIRACLE study in AML, it significantly broadens the story and shows that Annamycin's mechanism holds up even outside hematology. For me, it's a clear de-risking moment ahead of this summer's major unblinding.
- ·5.3.Any idea about upcoming price with good data and/or really good data?? And when? Q1 or Q2 2026?·18.3.Hoping for 3-5 USD and some preliminary data should come before Q2. I am still getting into the case so I have only put money into 500 units to start with today.
- ·14.1.MBRX – Moleculin: 0% cardiotoxicity confirmed + Phase 3 data underway – valuation isn't keeping up! Two press releases from Moleculin Biotech (MBRX) on January 12 & 13 have given us shareholders much to ponder – and even more to hope for. - January 12: The company presents its roadmap for 2026–2028. Focus on Annamycin (AML, STS, pancreatic cancer) and WP1066 (STAT3 inhibitor for brain tumors). The Phase 3 study MIRACLE is now global (9 countries, 46+ sites), and the first unblinding (45 patients) will occur Q1 2026. External studies underway via Atlantic Health, Emory, and Northwestern. - January 13: An independent expert confirms that Annamycin does not cause any cardiotoxicity – not even in patients who received doses far exceeding the FDA's lifetime limit for anthracyclines. 90 patients have now been evaluated, 65 of whom received >550 mg/m², one received >6500(!) mg/m² – without heart damage. What does this mean? - Annamycin could become the first truly non-cardiotoxic anthracycline – a class where heart damage is the biggest limitation. - The safety profile is now validated by an external expert – an important regulatory milestone. - The market potential is enormous: anthracyclines are used in ~50% of all cancer treatments, but are currently limited by cardiac side effects. - The MIRACLE study is well underway – efficacy data from the first 45 patients is expected Q1 2026. - External collaborations (Atlantic Health, Emory, Northwestern) provide validation and reduce capital requirements. Valuation – a ticking bomb? Moleculin is currently valued at approximately 12.5 MUSD. It is a Phase 3 company with a potential blockbuster in oncology – a market where similar companies are often valued at 10–20x more in the equivalent phase. Add to this: • A confirmed safety profile that eliminates one of the biggest regulatory risks. • A pipeline with several candidates (Annamycin, WP1066, WP1122). • A Phase 3 study that will soon be unblinded. • A potential first-in-class product in an area with a billion-dollar market. …and it's hard to understand why the market hasn't already started pricing this in. It smells like strong undervaluation. Risks remain: • Efficacy data is still crucial. Safety is necessary but not sufficient. • Moleculin is a microcap company without revenue – continued development requires capital or a partner. • The market has not yet reacted strongly – the stock even fell slightly on the news. Conclusion: Moleculin has now proven that Annamycin is safe for the heart – something no other anthracycline has achieved. If efficacy data from the MIRACLE study is also positive, this could be a paradigm shift in oncology. WP1066 is also a dark horse with the potential to break through in brain tumors and immunotherapy. It is high risk – but also high potential. 2026 could be the year Moleculin goes from being a speculative microcap to becoming an acquisition candidate or licensing partner for Big Pharma. This could be Moleculin's “make or break” year! MBRX – “Next-gen anthracycline”·23.2.I am on the same page and it is clear that the data could be even better, considering that the preliminary MIRACLE results indicate a CR/CRh frequency of 40%, significantly higher than the ~17–18% seen with standard treatment in relapsed AML. This suggests that Annamycin + cytarabine can provide significantly better efficacy than existing alternatives, which bodes well for the study's continuation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 24.3.2025 |
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.3. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 24.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23.4.Moleculin broadens the narrative: Annamycin opens the door to pancreatic cancer Moleculin Biotech (MBRX) today, April 23, 2026, presented new research results at the major cancer conference AACR. The results come from so-called preclinical studies, i.e., tests in a laboratory environment and on animals that are performed before a drug is tested on humans. The company's lead candidate Annamycin – in a form where the drug is packaged in small fat vesicles (liposomes) to reach better in the body – extended survival by more than 60% in models of metastatic pancreatic cancer (PDAC). The drug also accumulated to a significantly higher degree in the tumor itself compared to the classic cancer drug doxorubicin, which means that more of the effect ends up where it is needed. What is truly exciting is that Annamycin attracted the body's own immune cells (T-cells) into the tumor. Pancreatic cancer is often called a "cold" tumor – the immune system does not recognize it and does not attack. This is precisely why modern immunotherapies, so-called checkpoint inhibitors (for example, Keytruda), have so far worked poorly in this disease. If Annamycin can "warm up" the tumor and let in the immune system, a completely new treatment pathway opens up, especially in combination with today's modern cancer drugs such as checkpoint inhibitors and KRAS inhibitors (a new type that attacks a common cancer mutation). The competitive advantages are further strengthened. Annamycin does not damage the heart, which is the major limitation of today's anthracyclines and allows for higher and more doses. The drug also bypasses the resistance mechanisms that often cause cancer cells to stop responding to treatment upon relapse. Together with the new immunological effect, this makes Annamycin an interesting "backbone treatment" that can be combined with other modern drugs. The market potential is thus broadened from blood cancer to solid tumors, and pancreatic cancer is a multi-billion indication where the need for better treatments is enormous. Regulatorily, there are good opportunities to obtain special fast tracks at the FDA – such as Orphan Drug (for rare diseases), Fast Track, and possibly Breakthrough Therapy – all of which can shorten the time to approval and market. Looking ahead, three important events that could move the stock are expected: a poster presentation at the major cancer conference ASCO at the end of May on Annamycin's cardiac safety, the long-awaited interim readout of the MIRACLE study (the ongoing Phase 3 study in relapsed blood cancer, AML) on 45 patients around mid-2026, and possibly the kick-off for combination studies in solid tumors. The risks should not be underestimated – the company needs more funding going forward, and promising laboratory results do not always translate to success in humans. But if MIRACLE delivers, MBRX goes from an interesting small research stock to a validated Phase 3 case, and today's news shows that the pipeline holds more opportunities than what today's market capitalization reflects.
- ·23.4.@Drill do you have any thoughts on the good announcement from Moleculin? I'm thinking more specifically about the prestudy presentation they had today?·23.4.Yes, I think it's really good news. What makes the preclinical PDAC data extra interesting is not just the 60% survival extension but that Annamycin actually draws T-cells into the tumor. Pancreatic cancer is a classic “cold” tumor where checkpoint inhibitors have barely worked – if Annamycin can warm up the tumors, the door opens to combinations with Keytruda and KRAS inhibitors, which is precisely the type of backbone Big Pharma is looking for. I still want to remind you that it's preclinical – the path to the clinic is long, and that's where many oncology candidates fail. But as a complement to the ongoing MIRACLE study in AML, it significantly broadens the story and shows that Annamycin's mechanism holds up even outside hematology. For me, it's a clear de-risking moment ahead of this summer's major unblinding.
- ·5.3.Any idea about upcoming price with good data and/or really good data?? And when? Q1 or Q2 2026?·18.3.Hoping for 3-5 USD and some preliminary data should come before Q2. I am still getting into the case so I have only put money into 500 units to start with today.
- ·14.1.MBRX – Moleculin: 0% cardiotoxicity confirmed + Phase 3 data underway – valuation isn't keeping up! Two press releases from Moleculin Biotech (MBRX) on January 12 & 13 have given us shareholders much to ponder – and even more to hope for. - January 12: The company presents its roadmap for 2026–2028. Focus on Annamycin (AML, STS, pancreatic cancer) and WP1066 (STAT3 inhibitor for brain tumors). The Phase 3 study MIRACLE is now global (9 countries, 46+ sites), and the first unblinding (45 patients) will occur Q1 2026. External studies underway via Atlantic Health, Emory, and Northwestern. - January 13: An independent expert confirms that Annamycin does not cause any cardiotoxicity – not even in patients who received doses far exceeding the FDA's lifetime limit for anthracyclines. 90 patients have now been evaluated, 65 of whom received >550 mg/m², one received >6500(!) mg/m² – without heart damage. What does this mean? - Annamycin could become the first truly non-cardiotoxic anthracycline – a class where heart damage is the biggest limitation. - The safety profile is now validated by an external expert – an important regulatory milestone. - The market potential is enormous: anthracyclines are used in ~50% of all cancer treatments, but are currently limited by cardiac side effects. - The MIRACLE study is well underway – efficacy data from the first 45 patients is expected Q1 2026. - External collaborations (Atlantic Health, Emory, Northwestern) provide validation and reduce capital requirements. Valuation – a ticking bomb? Moleculin is currently valued at approximately 12.5 MUSD. It is a Phase 3 company with a potential blockbuster in oncology – a market where similar companies are often valued at 10–20x more in the equivalent phase. Add to this: • A confirmed safety profile that eliminates one of the biggest regulatory risks. • A pipeline with several candidates (Annamycin, WP1066, WP1122). • A Phase 3 study that will soon be unblinded. • A potential first-in-class product in an area with a billion-dollar market. …and it's hard to understand why the market hasn't already started pricing this in. It smells like strong undervaluation. Risks remain: • Efficacy data is still crucial. Safety is necessary but not sufficient. • Moleculin is a microcap company without revenue – continued development requires capital or a partner. • The market has not yet reacted strongly – the stock even fell slightly on the news. Conclusion: Moleculin has now proven that Annamycin is safe for the heart – something no other anthracycline has achieved. If efficacy data from the MIRACLE study is also positive, this could be a paradigm shift in oncology. WP1066 is also a dark horse with the potential to break through in brain tumors and immunotherapy. It is high risk – but also high potential. 2026 could be the year Moleculin goes from being a speculative microcap to becoming an acquisition candidate or licensing partner for Big Pharma. This could be Moleculin's “make or break” year! MBRX – “Next-gen anthracycline”·23.2.I am on the same page and it is clear that the data could be even better, considering that the preliminary MIRACLE results indicate a CR/CRh frequency of 40%, significantly higher than the ~17–18% seen with standard treatment in relapsed AML. This suggests that Annamycin + cytarabine can provide significantly better efficacy than existing alternatives, which bodes well for the study's continuation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt